Neil Gallagher

CIK: 0001972849

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)1 (16.7%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)5 (83.3%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (3)

FHTX

Foghorn Therapeutics Inc.

Director

SNDX

Syndax Pharmaceuticals Inc

Officer

ZYME

Zymeworks Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (6 total)

FHTX
Foghorn Therapeutics Inc.
Jun 24, 2026
Award(A)
Stock Options (Right to buy)
Direct
28K shares at avg. $4.08-
FHTX
Foghorn Therapeutics Inc.
May 1, 2025
Award(A)
Stock Options (Right to buy)
Direct
50K shares at avg. $4.16-
SNDX
Syndax Pharmaceuticals Inc
Feb 10, 2025
Sale(S)
Direct
4.6K shares at avg. $15.50$72K
SNDX
Syndax Pharmaceuticals Inc
Feb 5, 2025
Award(A)
Direct
18.5K shares-
SNDX
Syndax Pharmaceuticals Inc
Feb 5, 2025
Award(A)
Direct
23.4K shares-
ZYME
Zymeworks Inc.
Dec 10, 2024
Award(A)
Stock Option (Right to Buy)
Direct
31K shares-

		Type	Shares	Price		Ownership
Jun 24, 2026	FHTX Foghorn Therapeutics Inc.	Award(A) Stock Options (Right to buy)	28,000	$4.08	-	Direct
May 1, 2025	FHTX Foghorn Therapeutics Inc.	Award(A) Stock Options (Right to buy)	50,000	$4.16	-	Direct
Feb 10, 2025	SNDX Syndax Pharmaceuticals Inc	Sale(S)	4,618	$15.50	$71,597	Direct
Feb 5, 2025	SNDX Syndax Pharmaceuticals Inc	Award(A)	18,500	-	-	Direct
Feb 5, 2025	SNDX Syndax Pharmaceuticals Inc	Award(A)	23,400	-	-	Direct
Dec 10, 2024	ZYME Zymeworks Inc.	Award(A) Stock Option (Right to Buy)	31,000	-	-	Direct

1-6 of 6 transactions

About Gallagher Neil

Gallagher Neil (SEC CIK 0001972849) files insider reports with the SEC as Director of Foghorn Therapeutics Inc. (FHTX), President, Head of R&D of Syndax Pharmaceuticals Inc (SNDX) and Director of Zymeworks Inc. (ZYME).

Signal8 holds 6 ownership filings by Gallagher Neil (1 Form 3, 5 Form 4), filed between Dec 12, 2024 and Jun 25, 2026. Those filings report 6 transactions, from Dec 10, 2024 to Jun 24, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Gallagher Neil's filings is in WATERTOWN, MA.

Recent filings by Gallagher Neil

Jun 24, 2026: Grant or award of FHTX derivative securities (Form 4, code A).
May 1, 2025: Grant or award of FHTX derivative securities (Form 4, code A).
Feb 10, 2025: Open-market sale of SNDX shares (Form 4, code S).
Feb 5, 2025: Grants or awards of SNDX shares (2 lines, Form 4, code A).
Dec 10, 2024: Grant or award of ZYME derivative securities (Form 4, code A).

Other insiders filing for Foghorn Therapeutics Inc. (FHTX)

BVF PARTNERS L P/IL, 10% Owner
Lynch Thomas J. Jr., Director
Duty Stuart, Director
Biller Scott, Director
Mendelsohn Michael, Director
SMITH IAN F, Director

How to read Form 4 transaction codes